Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02422290

Organisation Name: New York State Psychiatric Institute

Overal Status: Completed

Start Date: March 2015

Last Update: August 17, 2020

Lead Sponsor: New York State Psychiatric Institute

Brief Summary: This pilot study is proposed to determine the acceptability, feasibility and potential efficacy of ketamine, a medication that modulates glutamate in the brain, as a rapid treatment for obsessive-compulsive disorder (OCD) symptoms in adolescents and young adults with OCD. This study will recruit 6 youth (ages 14-22) who are diagnosed with clinically significant OCD and have failed at least one adequate trial of a Serotonin Reuptake Inhibitor (SRI) medication and a course of Cognitive-Behavioral Therapy (CBT) (unless unable to access or tolerate) for OCD in the past. Participants will receive a single infusion of intravenous ketamine and be assessed at regular intervals post-infusion for up to 14 days. At the end of the 14-day treatment phase, all participants will be offered three months of open treatment for OCD with medication and/or CBT.

Conditions:
  • Obsessive-Compulsive Disorder


Total execution time in seconds: 0.16846394538879